Biomea Fusion, Inc. (BMEA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
Biomea Fusion, Inc. (NASDAQ:BMEA ) Citi's 2025 SMID Cap Biopharma Call Series October 23, 2025 11:00 AM EDT Company Participants Ramses Erdtmann - Co-Founder, President, COO & Director Thorsten Kirschberg - Executive Vice President of Chemistry Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. Hi, everyone.
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
The heavy selling pressure might have exhausted for Biomea Fusion (BMEA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Biomea's icovamenib meets HbA1c standards in T2D, says H.C. Wainwright
Biomea on Tuesday announced positive topline results from its Phase 2 COVALENT-111 trial evaluating icovamenib in patients with type 2 diabetes, with key takeaways including icovamenib displaying a statistically significant placebo-adjusted mean HbA1c reduction of 0.36% in the pre-specified per-protocol patient population and reduction of 0.42% after 12 weeks of treatments, H.C. Wainwright tells investors. Topline COVALENT-111 results validate the potential of icovamenib for long-term glycemic control with short-term treatment duration, the firm says. H.C. Wainwright made no change to its Buy rating or $40 price target.
